Inside AbZelectPRO™: The Next-Gen Cell Line Development Platform Fueling Biologics Success

In today’s rapidly evolving biopharmaceutical landscape, the pressure to accelerate timelines and improve reliability in cell line development (CLD) has never been more intense. Achieving high-yielding, stable cell lines quickly is critical to supporting faster IND submissions and enabling earlier clinical development. In this engaging conversation, Brett Verstak, Director of Cell Line Development at Abzena, and Jonathan Frampton, Vice President of Business Development at ProteoNic, explore how innovative strategies and technology partnerships are reshaping the CLD landscape.

At the heart of this transformation is AbZelectPRO™, a next-generation CLD platform born from the collaboration between Abzena and ProteoNic. By integrating Abzena’s optimized CHO-K1 host cell line with ProteoNic’s proprietary 2G UNic® vector technology, AbZelectPRO™ delivers a powerful combination of speed, productivity, and genetic stability. This platform has been fine-tuned to support a wide range of therapeutic modalities — from standard monoclonal antibodies to complex and difficult-to-express proteins — making it a flexible and scalable solution for today’s biologics developers.

Throughout the discussion, Verstak and Frampton highlight how AbZelectPRO™ helps overcome traditional bottlenecks in protein expression, enabling the development of robust cell lines in as little as 10 weeks. They also share real-world insights into the platform’s performance, including its ability to rescue commercially unviable programs and support late-stage regulatory filings.

Whether you're navigating the challenges of complex biologics or simply seeking a faster, more integrated path to the clinic, this conversation sheds light on how strategic innovation in CLD can be a game-changer for your pipeline.